Sanofi (Brazil)

Recent papers from Sanofi (Brazil)

1. Pharmacodynamics of Caplacizumab in Healthy Volunteers and Phase 2/3 Trial Patients with Immune-mediated Thrombotic Thrombocytopenic PurpuraThrombosis and Haemostasis · 2026
2. A Retrospective Chart Review Study on the Burden of Illness of Acid Sphingomyelinase Deficiency in BrazilJournal of Clinical Medicine · 2026
3. Parental perceptions of adverse events associated with the whole-cell pertussis vaccine in BrazilVaccine · 2026
4. Global trends in e-labeling: a comprehensive geographical perspectiveFrontiers in Medicine · 2025
5. Detection of gene variants associated with recessive limb–girdle muscular weakness and Pompe disease in a global cohort of patients through the application of next-generation sequencing analysisFrontiers in Genetics · 2024
6. Epidemiology of Pertussis After the COVID-19 Pandemic: Analysis of the Factors Involved in the Resurgence of the Disease in High-, Middle-, and Low-Income CountriesSHILAP Revista de lepidopterología · 2024
7. Polio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 PandemicVaccines · 2024
8. Assessment of combined α-GAL enzyme activity and lyso-GL3 for Fabry disease screening in women with chronic kidney diseaseMolecular Genetics and Metabolism · 2024
9. Acid sphingomyelinase deficiency in France: a retrospective survival studyOrphanet Journal of Rare Diseases · 2024
10. Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetesDiabetology & Metabolic Syndrome · 2024
11. Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpuraResearch and Practice in Thrombosis and Haemostasis · 2024
12. Natural history of acid sphingomyelinase deficiency among European patients during childhood and adolescence: A retrospective observational studyEuropean Journal of Medical Genetics · 2024
13. Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher RegistryAmerican Journal of Hematology · 2024
14. A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in GermanyOrphanet Journal of Rare Diseases · 2024
15. Multinational experience with next-generation sequencing: opportunity to identify transthyretin cardiac amyloidosis and Fabry diseaseCardiovascular Diagnosis and Therapy · 2024
16. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza seasonHuman Vaccines & Immunotherapeutics · 2024
17. Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)The European Journal of Health Economics · 2024
18. Algorithm for Investigation of Fabry Disease in CardiomyopathiesJournal of Inborn Errors of Metabolism and Screening · 2024
19. Worldwide Regulatory Reliance: Launching a Pilot on a Chemistry, Manufacturing, and Control Post Approval Change for a VaccinePDA Journal of Pharmaceutical Science and Technology · 2023
20. The Role of Adamts13 Activity Levels on Disease Exacerbation or Relapse in Patients With Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 Hercules and Post-Hercules StudiesHematology Transfusion and Cell Therapy · 2023